The popularity of Sildenafil initially fueled a surge for major pharmaceutical companies, but recent shifts present a uncertain outlook for investors. Lower-cost alternatives are eating into revenue, and continued https://barrybbaf952176.jiliblog.com/97577328/sildenafil-and-big-pharma-a-risky-bet